A phase I dose escalation study of ARQ 171 in adult patients with advanced solid tumors
Phase of Trial: Phase I
Latest Information Update: 08 Mar 2017
At a glance
- Drugs ARQ 171 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors ArQule
- 12 May 2008 Status changed from suspended to discontinued as ArQule state they will no longer pursue clinical testing of ARQ 171.
- 20 Mar 2008 Status changed from recruiting to suspended, in accordance with clinicaltrials.gov.
- 26 Nov 2006 New trial record.